Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

CPIX / Cumberland Pharmaceuticals Inc. ER

2018-02-14 sec.gov
November 17, 2017 A.J. Kazimi Chairman of the Board and Chief Executive Officer Cumberland Pharmaceuticals Inc. 2525 West End Avenue, Suite 950 Nashville, Tennessee 37203 Re: Cumberland Pharmaceuticals Inc. Registration Statement on Form S-3 Filed November 7, 2017 File No. 333-221402 Dear Mr. Kazimi: We have limited our review of your registration statement to those issues we have addressed in our comments.

CPIX / Cumberland Pharmaceuticals Inc. ESP

2018-02-14 sec.gov
Document ADAMS AND REESE LLP December 18, 2017 Ms. Suzanne Hayes Assistant Director United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3628     Re: Cumberland Pharmaceuticals Inc.     Registration Statement on Form S-3     Filed November 7, 2017     File No. 333-221402 Dear Ms. Hayes: On behalf of Cumberland Pharmaceuticals Inc.

CPIX / Cumberland Pharmaceuticals Inc. ESP

2018-02-14 sec.gov
Document ADAMS AND REESE LLP December 29, 2017 Ms. Suzanne Hayes Assistant Director United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3628     Re: Cumberland Pharmaceuticals Inc.     Registration Statement on Form S-3     Filed November 7, 2017     File No. 333-221402 Dear Ms. Hayes: On behalf of Cumberland Pharmaceuticals Inc.

CPIX / Cumberland Pharmaceuticals Inc. ESP

2018-02-14 sec.gov
Document January 11, 2018 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549-7010 Attention: Ms. Suzanne Hayes   Re: Cumberland Pharmaceuticals Inc.     Registration Statement on Form S-3     Filed November 7, 2017, amended on December 19, 2017 and January 8, 2018     File No. 333-221402     REQUEST FOR ACCELERATION OF EFFECTIVENESS Ladies and Gentlemen: Cumberland Pharmaceuticals Inc.

CPIX / Cumberland Pharmaceuticals Inc. / Stonepine Capital Management, LLC - 3G/A (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*     Cumberland Pharmaceuticals Inc. (Name of Issuer)     Common stock, no par value (Title of Class of Securities)     230770109 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   [X]       Rule 13d-1(b)   [X]       Ru

CPIX / Cumberland Pharmaceuticals Inc. / Stonepine Capital Management, LLC - 3G/A (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*     Cumberland Pharmaceuticals Inc. (Name of Issuer)     Common stock, no par value (Title of Class of Securities)     230770109 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   [X]       Rule 13d-1(b)   [X]       Ru

CPIX / Cumberland Pharmaceuticals Inc. / ARIEL INVESTMENTS, LLC - SC13GA CUMBERLAND PHARM DEC17 (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.7)* Cumberland Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 230770109 (CUSIP Number) 12/31/2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [_] Rule 13d-1(c) [_] Rule 13d-1(d) The remainder of this cover

CPIX / Cumberland Pharmaceuticals Inc. / ARIEL INVESTMENTS, LLC - SC13GA CUMBERLAND PHARM DEC17 (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.7)* Cumberland Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 230770109 (CUSIP Number) 12/31/2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [_] Rule 13d-1(c) [_] Rule 13d-1(d) The remainder of this cover

CPIX / Cumberland Pharmaceuticals Inc. / CUMBERLAND PHARMACEUTICALS INC - SC 13G - AJ KAZIMI 2017 (Passive Investment)

2018-02-09 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   __________________________________________   SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)*  __________________________________________ Cumberland Pharmaceuticals Inc.  _______________________________________ (Name of Issuer) Common Stock  __________________________________________ (Title of Class of Securities) 230770109 __________________________________________ (CUSIP Number) December

CPIX / Cumberland Pharmaceuticals Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-09 fintel.io
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) has 39 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 5,397,078 shares. Largest shareholders include Stonepine Capital Management, LLC, Dimensional Fund Advisors Lp, Ariel Investments, Llc, BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc, Bridgeway Capital Management Inc, JW Asset Management, LLC, New York State Common Retirement Fund, and Acadian Asset Management Llc. (32-0)

CPIX / Cumberland Pharmaceuticals Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A (Passive Investment)

2018-02-09 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. 2)*       CUMBERLAND PHARMACEUTICALS (Name of Issuer)   Common Stock (Title of Class of Securities)     230770109                                 (CUSIP Number)                                   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Sc

CPIX / Cumberland Pharmaceuticals Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A (Passive Investment)

2018-02-09 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. 2)*       CUMBERLAND PHARMACEUTICALS (Name of Issuer)   Common Stock (Title of Class of Securities)     230770109                                 (CUSIP Number)                                   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Sc

CPIX / Cumberland Pharmaceuticals Inc. 8-K - AMIFOSTINE STUDY (Current Report)

2018-02-02 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported):   February 2, 2018 (January 30, 2018) Cumberland Pharmaceuticals Inc. __________________________________________ (Exact name of registrant as specified in its charter)       Tennessee 001-33637 62-1765329   (State or other jurisdiction of incorporation) (Commission File N

Cumberland Pharmaceuticals: No Reason To Turn Bullish After Q3

2018-01-22 seekingalpha
But the company is buying those revenues: earnings are down, and the legacy portfolio is collapsing. (35-1)

CPIX / Cumberland Pharmaceuticals Inc. FORM S-3/A

2018-01-09 sec.gov
Form S-3/A Table of Contents As filed with the Securities and Exchange Commission on January 8, 2018 Registration No. 333-221402       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Amendment No. 2 Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933     CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter)       Tennessee   62-1765329 (State or other jurisdiction of incorporation or organization)   (IRS Employer Identific


CUSIP: 230770109